Biogen vs Scholar Rock
BIIB and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and SRRK compare
Biogen is the larger company, worth 6.8 times as much as Scholar Rock ($37.1B against $5.5B).
Biogen scores higher on the StockData Score (4 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $37.1B | $5.5B |
| Share price | $250.79 | $45.08 |
| Change, 1 year | 49.7% | 20.5% |
| Change, 5 years | 3.2% | 67.1% |
| Beta (5Y) | 0.14 | 0.83 |
| Employees | 7,500 | 289 |
| StockData Score | ||
| Total score | 4 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 107× | – |
| P/S | 3.6× | – |
| P/B | – | 21.6× |
| EV/EBITDA | 21.9× | – |
| P/FCF | 17.9× | – |
| FCF yield | 5.6% (better) | −5.4% |
| Fair value | $160.54 | – |
| Margin of safety | −56.2% | – |
| Growth | ||
| Revenue growth (TTM) | 2.3% | – |
| Revenue growth, 5Y average | −6.0% | – |
| Net income growth (TTM) | −78.4% | – |
| EPS growth (TTM) | −78.7% | – |
| EPS growth, 5Y average | −18.7% | – |
| Profitability | ||
| Gross margin | 74.0% | – |
| Net margin | 3.4% | – |
| FCF margin | 20.1% | – |
| Return on equity | – | −168% |
| Financial health | ||
| Debt / equity | – | 0.77 |
| Interest coverage | – | −38.0× |
| Current ratio | 1.95 | 7.02 (better) |
| Altman Z-score | 3.07 | 6.59 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −4.6% |
| Shareholder yield | 0.00% (better) | −4.6% |
| Ownership | ||
| Held by institutions | 96.2% | 114% |
| Held by insiders | 0.21% | 28.9% |
| Insider net buying, 12 months | −$905K (better) | −$7.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.7% | 27.1% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.